Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial

Pamela S. Douglas, Triin Umbleja, Gerald S. Bloomfield, Carl J. Fichtenbaum, Markella V. Zanni, Edgar T. Overton, Kathleen V. Fitch, Emma M. Kileel, Judith A. Aberg, Judith Currier, Craig A. Sponseller, Kathleen Melbourne, Anchalee Avihingsanon, Flavio Bustorff, Vicente Estrada, Kiat Ruxrungtham, Maria Saumoy, Ann Marie Navar, Udo Hoffmann, Heather J. RibaudoSteven Grinspoon

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


Background. In addition to traditional cardiovascular (CV) risk factors, antiretroviral therapy, lifestyle, and human immunodeficiency virus (HIV)-related factors may contribute to future CV events in persons with HIV (PWH). Methods. Among participants in the global REPRIEVE randomized trial, we characterized demographics and HIV characteristics relative to ACC/AHA pooled cohort equations (PCE) for atherosclerotic CV disease predicted risk and CV health evaluated by Life’s Simple 7 (LS7; includes smoking, diet, physical activity, body mass index, blood pressure, total cholesterol, and glucose). Results. Among 7382 REPRIEVE participants (31% women, 45% Black), the median PCE risk score was 4.5% (lower and upper quartiles Q1, Q3: 2.2, 7.2); 29% had a PCE score <2.5%, and 9% scored above 10%. PCE score was related closely to known CV risk factors and modestly (<1% difference in risk score) to immune function and HIV parameters. The median LS7 score was 9 (Q1, Q3: 7, 10) of a possible 14. Only 24 participants (0.3%) had 7/7 ideal components, and 36% had ≤2 ideal components; 90% had <5 ideal components. The distribution of LS7 did not vary by age or natal sex, although ideal health was more common in low sociodemographic index countries and among Asians. Poor dietary and physical activity patterns on LS7 were seen across all PCE scores, including the lowest risk categories. Conclusions. Poor CV health by LS7 was common among REPRIEVE participants, regardless of PCE. This suggests a critical and independent role for lifestyle interventions in conjunction with conventional treatment to improve CV outcomes in PWH.

Original languageEnglish
Pages (from-to)2009-2022
Number of pages14
JournalClinical Infectious Diseases
Issue number11
StatePublished - 1 Dec 2021


  • atherosclerotic cardiovascular disease
  • cardiac prevention
  • cardiovascular health
  • cardiovascular risk
  • lifestyle modifications


Dive into the research topics of 'Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial'. Together they form a unique fingerprint.

Cite this